第二代临时植入镍钛装置缓解良性前列腺增生相关下尿路症状:前瞻性多中心研究1年随访结果
这项前瞻性多中心研究评估了第二代临时植入镍钛装置(iTIND)治疗良性前列腺增生(BPH)所致下尿路症状(LUTS)的1年随访效果。81例患者植入iTIND,5-7天后取出,12个月时Qmax从基线7.3 mL/s增至14.7 mL/s(+100%),IPSS从22.5降至8.8(-60%),无Clavien-Dindo >II级并发症,性功能与射精功能完全保留。
要点
- iTIND植入安全可行,12个月时Qmax翻倍、IPSS降低60%。
- 无Clavien-Dindo >II级并发症,性功能与射精功能完全保留。
- 12个月内2.4%需药物治疗BPH,2.4%需经尿道前列腺电切术。
核心结论
- iTIND植入在术后至少12个月内能安全有效地缓解BPH相关症状,且性功能和射精功能完全保留。
研究设计与样本
- 前瞻性、多中心、伦理委员会批准的研究,纳入81例LUTS患者,IPSS≥10、Qmax≤12 mL/s、前列腺体积<75 mL。
主要发现
- 平均Qmax从基线7.3 mL/s增至1个月11.2 mL/s和12个月14.7 mL/s(+100%)。
- 平均IPSS从基线22.5降至1个月11.7和12个月8.8(-60%)。
- 平均IPSS QoL评分至研究结束时下降1.6。
- 12个月内2例(2.4%)需BPH药物治疗,2例(2.4%)需经尿道前列腺电切术,10例(12.3%)失访。
- 61例完成12个月随访的性活跃患者中,无一人报告性功能或射精功能障碍。
临床怎么用
- 对于前列腺体积<75 mL、无梗阻性中叶、无既往前列腺手术史的BPH/LUTS患者,iTIND可作为保留性功能的微创治疗选择。
局限性
- 随访仅12个月,需更长期研究评估疗效持久性并明确iTIND植入适应证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To report the clinical experience with a second-generation of temporary implantable nitinol device (iTIND; Medi-Tate Ltd, Or-Akiva, Israel) for the treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) after 1 year of follow-up. PATIENTS AND METHODS: In all, 81 patients with LUTS, International Prostate Symptom Score (IPSS) ≥10, maximum urinary flow rate (Qmax ) ≤12 mL/s, and prostate volume <75 mL, were enrolled in this prospective Research Ethics Committee-approved multicentre study. The main exclusion criteria were: haemostatic disorders, post-void residual urine volume (PVR) >250 mL, obstructive median lobe, and previous prostate surgery. The iTIND was implanted within the bladder neck and the prostatic urethra under light sedation, using a rigid cystoscope. The device was removed 5-7 days later in an outpatient setting. Demographics, perioperative results, complications (according to the Clavien-Dindo system), functional results and quality of life (QoL) were evaluated. Follow-up assessments were conducted at 1, 3, 6 and 12 months postoperatively. RESULTS: The mean (sd) patient age was 65 (8.9) years, prostate volume was 40.5 (12.25) mL, Qmax was 7.3 (2.6) mL/s, IPSS was 22.5 (5.6), and the median (interquartile range) IPSS QoL score was 4 (2-5). All the implantations were successful, with no intraoperative complications recorded; all patients were discharged on the same day of surgery. The devices were retrieved at a mean (SD) of 5.9 (1.1) days after implantation, typically under topical anaesthesia. No Clavien-Dindo Grade >II complications were recorded. The mean (SD) Qmax at the 1 month follow-up visit was 11.2 (5.7) mL/s and continued to improve thereafter, reaching 14.7 (8.1) mL/s at the 12-month follow-up visit (+100%). The mean (SD) IPSS urinary symptom scores were 11.7 (8.0) after 1 month and further improved to 8.8 (6.4) at the 12-month follow-up (-60%). In parallel, the mean (SD) IPSS QoL score drop reached 1.6 (1.3) by the end of the study. During the 12-month period, two patients (2.4%) required medical therapy for BPH, two patients (2.4%) required transurethral resection of the prostate, whilst 10 patients were lost to follow-up (12.3%). As compared to baseline, none of the 61 sexually active patients who completed the 12-month follow-up period reported sexual or ejaculatory dysfunction. CONCLUSION: iTIND implantation is feasible, safe and effective in providing relief of BPH-related symptoms, at least until 12 months postoperatively. Sexual and ejaculatory functions are fully preserved. Further studies with a longer follow-up period are needed to assess the durability of these results and to clearly define the indications for iTIND implantation.
引用
- Porpiglia F, Fiori C, Amparore D, et al. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. BJU Int. 2018. PMID: 30382600. doi:10.1111/bju.14608
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。